First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer
Conclusions ASP4132 showed limited clinical activity, and DLTs prohibited dose escalation. Further research is required to determine if DLTs will limit clinical activity of other mitochondrial complex I inhibitors.Clinical Trial ID (clinicaltrials.gov): NCT02383368, March 9, 2015.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Drugs & Pharmacology | Investigational New Drugs | Men | Mitochondrial Disease | Oral Cancer | Study | Toxicology